Imagine a smoke detector for the brain that catches a fire before it spreads. Instead of waiting for severe memory loss, this system uses simple blood tests and app-based brain games to spot warning signs early. It then suggests a personalized plan to lower the risk of dementia through lifestyle changes.
Current Alzheimer's detection happens too late, and existing diagnostic methods are often too expensive or invasive for mass screening. This leads to missed opportunities for prevention and high costs for healthcare systems.
A modular toolbox containing a digital engagement platform, blood-based biomarker protocols, and digital cognitive assessment tools.
If you are a lab provider dealing with the high cost of traditional dementia imaging — this project developed blood-based biomarkers (BBMs) that provide a more cost-effective way to screen for Alzheimer's risk.
If you are a software company dealing with a lack of clinically validated screening tools — this project developed digital cognitive assessments (DCAs) that can be deployed across diverse patient populations.
If you are a pharma company dealing with the difficulty of finding the right patients for clinical trials — this project developed algorithms to identify people who can benefit from specific preventive therapies.
Based on available project data, the specific price per test is not listed, but the project aims to provide 'cost-effective' testing compared to current methods.
Yes, the project objective explicitly states that the modular design is intended for scalability to other dementias.
Based on available project data, specific licensing terms are not provided, though the project involves 10 industry partners who may hold related IP.
The project uses a modular toolbox platform designed for broad uptake across different healthcare settings and practitioners.
The project runs from 2024-01-01 to 2028-12-31, suggesting that full validation and real-world testing will conclude by the end of 2028.
The consortium is heavily geared toward commercialization, with a 36% industry ratio comprising 10 companies, including 5 SMEs. With 28 partners across 12 countries, the project has a strong international footprint and a balanced mix of 8 universities and 5 research institutes to ensure scientific validity alongside market viability.
Contact Region Stockholm in Sweden for partnership inquiries.
Contact us to find a partner for the large-scale testing phase of AD-RIDDLE.
